Autor
Marcus M. Reidenberg, del Departamento de Farmacología y Medicina de la Facultad de Medicina de la Universidad Cornell (Nueva York), es el editor de este volumen número 4 de la serie Esteve Foundation Symposia. Las nuevas técnicas de biología molecular y celular presentan diversas oportunidades para el desarrollo de nuevos agentes para el diagnóstico, el tratamiento y la prevención de enfermedades. Cómo extrapolar el potencial de la moderna ciencia biomédica a la realidad para poder mejorar la salud de las personas es el objetivo de los farmacólogos clínicos, físicos e investigadores de la nueva biología que se reunieron en el simposio internacional organizado por la Fundación Dr. Antonio Esteve en octubre de 1990.
Capítulos | ||
Introduction | M.M. Reidenberg | [wpdm id=145 type=”btn”] |
List of participants | [wpdm id=146 type=”btn”] | |
1. Purification of Proteins: Converting a culture broth into a medicine | R.G. Werner | [wpdm id=123 type=”btn”] |
2. Human insulin and its modifications | J.A. Galloway / R.E. Chance / K.S.E. Su | [wpdm id=124 type=”btn”] |
3. the use of recombinant proteins in Aids research: Developtment of a CD4/GP120 binding assay | J. Mous / C. Manzoni / L. Dirckx | [wpdm id=125 type=”btn”] |
4. FGF receptors as targets for drug development | C.A. Dionne / M. Jaye / J. Schlessinger | [wpdm id=126 type=”btn”] |
5. Development of antagonists for IFNy and TNF | M. Steinmetz | [wpdm id=127 type=”btn”] |
6. Proteins in search of a disease | L. Gauci | [wpdm id=128 type=”btn”] |
7. Absorption of therapeutic peptides | B.R. Meyer | [wpdm id=129 type=”btn”] |
8. Pharmacokinetics of human tissue-type plasminogen activator | P. Tanswell / E. Seifried / J. Krause | [wpdm id=130 type=”btn”] |
9. Role of the Kidney in Eliminating Proteins and Peptides | D.C. Brater | [wpdm id=131 type=”btn”] |
10. Possible problemas associated with Cytokine contamination of biotechnology products | A. Gearing / M. Wadhwa / R. Thorpe | [wpdm id=132 type=”btn”] |
11. Selection of animal species and length of toxicity studies with recombinant proteins. Review of industry and regulators\’ approach and case history of Rec-Hirudin | P. Graepel / F. Pfannkuch / R. Hess | [wpdm id=133 type=”btn”] |
12. Toxicological development of hematopoietic growth factors | H. Ronneberger | [wpdm id=134 type=”btn”] |
13. Meaningful evaluation of biotechnology products | P. Juul | [wpdm id=135 type=”btn”] |
14. Biological and clinical response of recombinant interferon gamma in patients with advanced renal cell cancer | W. Aulitzky / G. Gastl / W.E. Aulitzky / J. Prick / C. Huber | [wpdm id=136 type=”btn”] |
15. Tissue-Type Plasminogen Activator | H.R. Lijnen / D. Collen | [wpdm id=137 type=”btn”] |
16. Erythropoietin | F. Valderrabano | [wpdm id=138 type=”btn”] |
17. Clinical Pharmacology of Hirudin (HBW 023) | H.J. Roethig / J.S. Maree / B.H. Meyer | [wpdm id=139 type=”btn”] |
18. Therapeutic actions of recombinant human granulocyte-Macrophage colony-stimulating factor (GM-CSF) | A. Ganser / D. Hoelzer | [wpdm id=140 type=”btn”] |
19. Potential use of Peptide hormones in sport | J. Segura / R. de la Torre / R. Badia | [wpdm id=141 type=”btn”] |
20. Costs of discovering, developing, manufacturing and marketing biotechnology products | W.M. Wardell | [wpdm id=142 type=”btn”] |
21. The impact of economic issues on the therapeutic usage of biotechnology products. A view from the hospital | M. Levy / S. Penchas | [wpdm id=143 type=”btn”] |
22. Biotechnological products, Can this commodity be afforded? | F. García Alonso | [wpdm id=144 type=”btn”] |
- 2. Human insulin and its modifications
- J.A. Galloway / R.E. Chance / K.S.E. Su
- Descargar
- 10. Possible problemas associated with Cytokine contamination of biotechnology products
- A. Gearing / M. Wadhwa / R. Thorpe
- Descargar
- 19. Potential use of Peptide hormones in sport
- J. Segura / R. de la Torre / R. Badia
- Descargar
- 3. the use of recombinant proteins in Aids research: Developtment of a CD4/GP120 binding assay
- J. Mous / C. Manzoni / L. Dirckx
- Descargar
- 12. Toxicological development of hematopoietic growth factors
- H. Ronneberger
- Descargar
- 20. Costs of discovering, developing, manufacturing and marketing biotechnology products
- W.M. Wardell
- Descargar
- 4. FGF receptors as targets for drug development
- C.A. Dionne / M. Jaye / J. Schlessinger
- Descargar
- 13. Meaningful evaluation of biotechnology products
- P. Juul
- Descargar
- 21. The impact of economic issues on the therapeutic usage of biotechnology products. A view from the hospital
- M. Levy / S. Penchas
- Descargar
- 5. Development of antagonists for IFNy and TNF
- M. Steinmetz
- Descargar
- 14. Biological and clinical response of recombinant interferon gamma in patients with advanced renal cell cancer
- W. Aulitzky / G. Gastl / W.E. Aulitzky / J. Prick / C. Huber
- Descargar
- 22. Biotechnological products, Can this commodity be afforded?
- F. García Alonso
- Descargar
- 6. Proteins in search of a disease
- L. Gauci
- Descargar
- 15. Tissue-Type Plasminogen Activator
- H.R. Lijnen / D. Collen
- Descargar
- The clinical pharmacology of biotechnology products Introduction
- M.M. Reidenberg
- Descargar
- 7. Absorption of therapeutic peptides
- B.R. Meyer
- Descargar
- 16. Erythropoietin
- F. Valderrabano
- Descargar
- The clinical pharmacology of biotechnology products List of participants
- Descargar
- 8. Pharmacokinetics of human tissue-type plasminogen activator
- P. Tanswell / E. Seifried / J. Krause
- Descargar
- 17. Clinical Pharmacology of Hirudin (HBW 023)
- H.J. Roethig / J.S. Maree / B.H. Meyer
- Descargar
- 1. Purification of Proteins: Converting a culture broth into a medicine
- R.G. Werner
- Descargar
- 9. Role of the Kidney in Eliminating Proteins and Peptides
- D.C. Brater
- Descargar
- 18. Therapeutic actions of recombinant human granulocyte-Macrophage colony-stimulating factor (GM-CSF)
- A. Ganser / D. Hoelzer
- Descargar